DOx

Use and effects

Side effects

DOx drugs like DOM have been associated with certain side effects that have not occurred to the same extent with other psychedelics like LSD. Examples of such side effects include physical symptoms like sweating, tremors, and large increases in heart rate.

Interactions

Pharmacology

Pharmacodynamics

Actions

The DOx drugs act as agonists of the serotonin 5-HT2 receptors, including of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors. Their psychedelic effects are thought to be mediated specifically by activation of the serotonin 5-HT2A receptor.

In contrast to other amphetamines, DOx drugs like DOC, DOET, and DOM are inactive as monoamine releasing agents and reuptake inhibitors. Some of the DOx drugs, including DOB, DOET, DOI, and DOM, are agonists of the rat, rhesus monkey, and/or human trace amine-associated receptor 1 (TAAR1) with varying potencies.

Effects

In contrast to amphetamines like (–)-cathinone, but similarly to mescaline, DOM has shown no stimulant-like or reinforcing effects in rhesus monkeys. Conversely however, DOC has shown reinforcing effects, including conditioned place preference (CPP) and self-administration, in rodents similarly to methamphetamine. This is analogous to other findings in which various 2C and NBOMe drugs have been found to produce brain dopaminergic elevations and reinforcing effects in rodents.

Pharmacokinetics

The DOx drugs are orally active and many have doses in the range of 1 to 10mg and durations in the range of 8 to 30hours. Some DOx drugs, such as DOM and DOB, appear to have durations that increase non-linearly with dose, for instance 8hours at lower doses and as long as 30hours or even up to 3 or 4days at higher doses. This suggests that the pathways mediating the metabolism of these drugs can saturate. The DOx drugs are metabolized primarily by O-demethylation. However, DOM is primarily metabolized by hydroxylation at its methyl group.

History

DOM was the first psychedelic of the DOx series to be discovered. It was first synthesized by Alexander Shulgin at Dow Chemical Company in 1963, who had had his first psychedelic experience, with mescaline (3,4,5-trimethoxyphenethylamine), in 1960. Shulgin personally tried DOM on January 4, 1964 and discovered its psychedelic effects. 2,4,5-Trimethoxyamphetamine (TMA-2; "DOMeO") had been synthesized by Bruckner in 1933, but its psychedelic effects were not described until Shulgin tried the compound and reported its effects in the scientific literature in 1964. Prior to this, 3,4,5-trimethoxyamphetamine (TMA; α-methylmescaline) had been synthesized by Hey in 1947, being found by him to produce euphoria, and was described by Peretz and colleagues in 1955 as clearly producing psychedelic effects.

Following his discovery of DOM, Shulgin developed DOET and found that at low doses it was a remarkable "psychic energizer" without producing psychedelic effects at these doses. Dow Chemical Company decided to move forward with clinical trials of DOET as a potential pharmaceutical drug for such purposes. Shulgin and Dow Chemical Company filed a patent for DOET in 1966, although it was not published until 1970. Dow Chemical Company tasked Solomon H. Snyder at Johns Hopkins University with clinically studying DOET.

In April 1967, following the banning of LSD in California in 1966, DOM emerged as a street drug and legal LSD alternative with the name "STP" (allegedly short for "Serenity, Tranquility, and Peace") in the Haight-Ashbury district in San Francisco. This occurred due to DOM being publicly distributed for free in the form of high-dose tablets by LSD distributor Owsley Stanley, who had personally learned of DOM from Shulgin. It is unclear why Shulgin provided information about DOM to Stanley, since doing so had the potential to risk Shulgin's professional career and the DOET clinical studies. One possibility is that Dow Chemical Company was not further looking into DOM and Shulgin thought that it was a promising drug that would otherwise be forgotten. In any case, street use of DOM was short-lived because the tablets caused a public health crisis due to them often producing very long durations (up to 3–4days), intense experiences, worrying physical side effects, and hospitalizations. DOM was first reported on in the media and scientific literature in 1967 as a result of the crisis. DOM became illegal in the United States in 1968.

Dow Chemical Company terminated its clinical research program on DOET due to the DOM public health crisis. DOET was subsequently first described in the literature by Snyder and colleagues in 1968. Snyder continued to be interested in DOET as a potential medicine, but it was never further developed. Snyder also described 2,5-dimethoxyamphetamine (2,5-DMA), which had been synthesized and tested by Shulgin, in the literature in 1968. DOM and DOET were further described in the scientific literature by Shulgin in 1969. In addition, Shulgin discussed DOM, DOET, TMA-2, and 2,5-DMA in a book chapter on hallucinogens published in 1970.

The earlier DOx drugs like DOM and DOET were subsequently followed by DOB, which was developed by Shulgin and colleagues like Claudio Naranjo, in 1971, and by DOI, DOC, and a few other analogues, which were developed by another research group, in 1973. After this, numerous other DOx drugs were synthesized and characterized, both by Shulgin and other scientists.

Following its discovery, DOI has become widely used in scientific research in the study of the serotonin 5-HT2 receptors.

Society and culture

Legal status

Canada

The DOx drugs are controlled substances as amphetamines in Canada.

List of DOx drugs

The DOx family includes the following members:

Related compounds

A number of additional compounds are known with alternative substitutions:

References

References

1. Daniel Trachsel. (2013). "Phenethylamine: Von der Struktur zur Funktion". Nachtschatten Verlag AG.
2. (February 2017). "Psychedelics as Medicines: An Emerging New Paradigm". Clin Pharmacol Ther.
3. (August 2018). "Psychedelics as anti-inflammatory agents". Int Rev Psychiatry.
4. (November 2008). "Serotonin 5-hydroxytryptamine(2A) receptor activation suppresses tumor necrosis factor-alpha-induced inflammation with extraordinary potency". J Pharmacol Exp Ther.
5. (February 2024). "Serotonin-2 Receptor Agonists Produce Anti-inflammatory Effects through Functionally Selective Mechanisms That Involve the Suppression of Disease-Induced Arginase 1 Expression". ACS Pharmacol Transl Sci.
6. (May 2020). "Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species". Neuropharmacology.
7. (1998). "Designer Drugs Directory". Elsevier Science.
8. (2012). "Fluorine in psychedelic phenethylamines". Drug Test Anal.
9. (2013). "Phenethylamine: von der Struktur zur Funktion". Nachtschatten-Verlag.
10. (December 1975). "Psychotomimetic phenylisopropylamines. 5. 4-Alkyl-2,5-dimethoxyphenylisopropylamines". J Med Chem.
11. (1978). "Mescaline analogs: substitutions at the 4-position". NIDA Res Monogr.
12. (January 1999). "Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors". Naunyn Schmiedebergs Arch Pharmacol.
13. (2023). "Binding and functional structure-activity similarities of 4-substituted 2,5-dimethoxyphenyl isopropylamine analogues at 5-HT2A and 5-HT2B serotonin receptors". Front Pharmacol.
14. (2022). "Structure-activity Relation of Halogenated 2,5-Dimethoxyamphetamines Compared to their α‑Desmethyl (2C) Analogues". The FASEB Journal.
15. (1997). "Pharmacochemistry Library". Elsevier.
16. (2022). "Monoamine Receptor and Transporter Interaction Profiles of 4-Alkyl-Substituted 2,5-Dimethoxyamphetamines". The FASEB Journal.
17. (February 2010). "Psychedelics and the human receptorome". PLOS ONE.
18. (9 March 2012). "Medical Toxicology of Drug Abuse: Synthesized Chemicals and Psychoactive Plants". Wiley.
19. (October 2020). "In vitro structure-activity relationship determination of 30 psychedelic new psychoactive substances by means of β-arrestin 2 recruitment to the serotonin 2A receptor". Arch Toxicol.
20. (2021). "Handbook of Medical Hallucinogens". Guilford Publications.
21. (June 2024). "1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI): From an Obscure to Pivotal Member of the DOX Family of Serotonergic Psychedelic Agents - A Review". ACS Pharmacol Transl Sci.
22. (March 2014). "Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function". Psychopharmacology (Berl).
23. (December 2018). "Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors". Biochem Pharmacol.
24. (December 2011). "Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class". Bioorg Med Chem.
25. (December 2001). "Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor". Mol Pharmacol.
26. (January 2008). "The behavioral pharmacology of hallucinogens". Biochem Pharmacol.
27. (January 2017). "The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens". J Psychopharmacol.
28. (June 1986). "Intravenous self-administration of (-)-cathinone and 2-amino-1-(2,5-dimethoxy-4-methyl)phenylpropane in rhesus monkeys". Drug Alcohol Depend.
29. (October 2024). "Evaluation of potential punishing effects of 2,5-dimethoxy-4-methylamphetamine (DOM) in rhesus monkeys responding under a choice procedure". Behav Pharmacol.
30. (May 2018). "Rewarding and reinforcing effects of 4-chloro-2,5-dimethoxyamphetamine and AH-7921 in rodents". Neurosci Lett.
31. (June 2025). "Toxicodynamic insights of 2C and NBOMe drugs - Is there abuse potential?". Toxicol Rep.
32. (April 2021). "New designer phenethylamines 2C-C and 2C-P have abuse potential and induce neurotoxicity in rodents". Arch Toxicol.
33. (November 2020). "25B-NBOMe, a novel N-2-methoxybenzyl-phenethylamine (NBOMe) derivative, may induce rewarding and reinforcing effects via a dopaminergic mechanism: Evidence of abuse potential". Addict Biol.
34. (October 2019). "A novel designer drug, 25N-NBOMe, exhibits abuse potential via the dopaminergic system in rodents". Brain Res Bull.
35. (November 2022). "Rewarding and Reinforcing Effects of 25H-NBOMe in Rodents". Brain Sci.
36. (August 2023). "Designer Drug, 25D-NBOMe, Has Reinforcing and Rewarding Effects through Change of a Dopaminergic Neurochemical System". ACS Chem Neurosci.
37. (April 2024). "The novel psychoactive substance 25E-NBOMe induces reward-related behaviors via dopamine D1 receptor signaling in male rodents". Arch Pharm Res.
38. (March 2022). "Trips and neurotransmitters: Discovering principled patterns across 6850 hallucinogenic experiences". Sci Adv.
39. (1994). "Structure-activity relationships of the classic hallucinogens and their analogs". NIDA Res Monogr.
40. (2012). "Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model". Drug Test Anal.
41. (9 June 2014). "Alexander Theodore Shulgin (1925-2014)".
42. Baggott, Matthew J.. (1 October 2023). "Learning about STP: A Forgotten Psychedelic from the Summer of Love". History of Pharmacy and Pharmaceuticals.
43. Bruckner, Viktor. (24 October 1933). "Über das Pseudonitrosit des Asarons". Journal für Praktische Chemie.
44. (July 1964). "Psychotomimetic amphetamines: methoxy 3,4-dialkoxyamphetamines". Experientia.
45. (April 1955). "A new hallucinogen: 3,4,5-trimethoxyphenyl-beta-aminopropane with notes on the stroboscopic phenomenon". J Ment Sci.
46. (1961). "The Psychotomimetic Properties of 3,4,5-Trimethoxyamphetamine". Nature.
47. (1947). "The synthesis of a new homologue of mescaline". Q J Pharm Pharmacol.
48. (1970). "phenethylamines and their pharmacologically-acceptable salts".
49. (December 2024). "The origin of 2,5-dimethoxy-4-methylamphetamine (DOM, STP)". Drug Test Anal.
50. (November 1967). "2,5-dimethoxy-4-methyl-amphetamine (STP): a new hallucinogenic drug". Science.
51. (September 1968). "DOM (STP), a new hallucinogenic drug, and DOET: effects in normal subjects". Am J Psychiatry.
52. (May 1968). "Psychedelic drugs: steric factors that predict psychotropic activity". Proc Natl Acad Sci U S A.
53. Shulgin, Alexander T.. (1969). "Psychotomimetic Agents Related to the Catecholamines". Journal of Psychedelic Drugs.
54. [[Alexander Shulgin]]. (1970). "Psychotomimetic Drugs". Raven Press.
55. (1971). "4-Bromo-2,5-dimethoxyphenylisopropylamine, a new centrally active amphetamine analog". Pharmacology.
56. (1 May 1973). "The Synthesis of Some Analogs of the Hallucinogen 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane (DOM)". Canadian Journal of Chemistry.
57. Shulgin, Alexander T.. (1978). "Stimulants". Springer US.
58. (1984). "Hallucinogens: Neurochemical, Behavioral, and Clinical Perspectives". Raven Press.
59. (1991). "PiHKAL: A Chemical Love Story". Transform Press.
60. (2011). "The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds". Transform Press.
61. (2018). "Chemistry and Structure-Activity Relationships of Psychedelics".
62. "Controlled Drugs and Substances Act".
63. Harms A, Ulmer E, Kovar K. Synthesis and 5-HT2A radioligand receptor binding assays of DOMCl and DOMOM, two novel 5-HT2A receptor ligands. ''Arch. Pharm''., 16 Jun 2003, 336(3): 155–158. {{doi. 10.1002/ardp.200390014
64. [https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2007038372 Hellberg M, Namil A, Feng Z, Ward J. Phenylethylamine Analogs and Their Use for Treating Glaucoma. Patent WO 2007/038372, 6 Apr 2007]
65. Trachsel D. Fluorine in psychedelic phenethylamines. ''Drug Test. Anal.'', 1 Jul 2012, 4(7-8): 577-590.{{doi. 10.1002/dta.413
66. Seggel MR, Yousif MY, Lyon RA, Titeler M, [[Bryan Roth. Roth BL]], Suba EA, Glennon, RA. A structure-affinity study of the binding of 4-substituted analogues of 1-(2,5-dimethoxyphenyl)-2-aminopropane at 5-HT2 serotonin receptors. ''J. Med. Chem.'', 1 Mar 1990, 33(3): 1032–1036. {{doi. 10.1021/jm00165a023
67. (August 2003). "Synthesis of Novel (Phenylalkyl) amines for the Investigation of Structure–Activity Relationships, Part 3: 4-Ethynyl-2,5-dimethoxyphenethylamine (= 4-Ethynyl-2, 5-dimethoxybenzeneethanamine; 2C-YN).". Helvetica Chimica Acta.
68. (2019). "Receptor Interaction Profiles of 4-Alkoxy-Substituted 2,5-Dimethoxyphenethylamines and Related Amphetamines". Front Pharmacol.
69. [https://patents.google.com/patent/US7396856 Hellberg MR, Namil A. Benzopyran analogs and their use for the treatment of glaucoma. Patent US 7396856]
70. [https://patentimages.storage.googleapis.com/a2/12/19/8424e3822cbe82/US20210137908A1.pdf Kristensen J, et al. 5-HT2A Agonists for Use in Treatment of Depression. Patent US 2021/0137908]